Imagine you’re a doc who’s sunk years — and probably a fortune — into perfecting a silicone sleeve for guys chasing that extra inch. Now the Federal Circuit is telling you: publish a patent on bits of it, and poof, your trade secrets vanish like a bad Tinder date.
That’s the gut punch from oral arguments in International Medical Devices v. Cornell. Real people? Inventors juggling patents and secrets for medical gadgets. You’re screwed if judges side with defendants.
Why Your Patent Might Be a Trade Secret’s Worst Enemy
Short answer: disclosure. Defendants scream that Dr. James Elist’s three design secrets for the Penuma — that FDA-cleared girth-booster — spilled out in prior patents. The fourth? An “instrument list” they call public knowledge anyway.
Judges Dyk, Taranto, Reyna hammered this during March 5 arguments. Under California’s Uniform Trade Secrets Act (CUTSA), once info’s public, it’s dead as a doornail for secrecy.
A jury found a group of defendants misappropriated four trade secrets belonging to Dr. James Elist, a Beverly Hills urologist who developed the Penuma cosmetic penile implant.
Jury bought it. Appeals court? Not so fast.
Here’s the tech, for the morbidly curious: Penuma’s a subcutaneous silicone sleeve, slipped between skin and Buck’s fascia. Boosts length, girth. Unlike ED implants buried deep in erectile tissue, this one’s superficial — gotta flex with erections, no erosion, no migration. Only FDA nod in its class. Fancy.
But defendants — International Medical Devices and crew — say Elist’s patents blabbed the designs. No secret left.
And.
This stinks of classic IP tug-of-war. Patent it? World knows, you get 20 years monopoly. Keep secret? Indefinite, but reverse-engineer at your peril. Elist tried both. Fed Cir’s sniffing which wins.
Oral args zeroed on CUTSA’s “publicly known” clause. Judges grilled: If patent apps detail concepts, is that game over as a matter of law? No jury needed?
Defendants push yes. Elist? Nu-uh, patents vague, secrets deeper.
Does the Penuma’s Weirdness Change Anything?
Penis tech. Always good for laughs — or winces. But strip the giggles: core issue’s universal. Medical devs everywhere patent prototypes, tweak in secret. This case tests if tweaks stay protectable.
Judges seemed skeptical. Taranto probed: “Isn’t the patent figure showing exact design?” Dyk wondered about instrument lists floating in med lit. Reyna? Standard trade secret skepticism.
Elist’s play: Patents cover broad strokes; secrets are implementation magic. Like Coke’s formula hiding behind vague patents.
My hot take — unmentioned in Patently-O’s teaser: This echoes the 1980s software wars. Lotus sued Borland over 1-2-3 menus. Supreme Court said no copyright on functional bits. Here, patents might neuter trade secrets same way. Bold prediction: If Cornell wins, expect a stampede to pure secrecy in medtech. No more half-patenting. Risky? Hell yes — one leak, and you’re cooked.
Corporate spin? Elist’s camp paints defendants as thieves ripping Penuma clones. But if patents disclosed? That’s not theft; that’s smart lawyering by rivals.
Look.
Real-world fallout. Urologists, cosmetic surgeons — your implant tweaks? Patent ‘em fully or lock ‘em down. Half-ass it, Fed Cir might half-ass your protection.
Broader? Biotech firms love this hybrid IP dance. Post-this, maybe not. Trade secrets boom, patent apps drop. FDA clearance? Still king, but IP armor thins.
What Oral Args Revealed (And What They Didn’t)
Dyk opened probing prior art. “If it’s in the patent, how’s it secret?” Defendants: Bingo. Elist: Different animal.
Taranto dove deep — classic him — on CUTSA’s “acquired by accident” exception. No dice if derived from public patents.
Reyna, ever practical: Instrument list? Sounds mundane, not secret.
No clear signals. But vibe? Leaning defendants. Patents as poison pills for secrets.
Missed in args: Penuma’s market. Elist’s Beverly Hills cash cow. Competitors circling with knockoffs. This ain’t abstract; it’s millions in silicone sleeves.
But here’s the kicker — my unique dig: Elist’s like that band that samples its own hit, then sues for theft. Patents are your sample release. Can’t cry secret later.
Historical parallel? Think Polaroid vs. Kodak. Patents litigated for years; secrets secondary. Fed Cir’s era might flip that script.
Why Does This Matter for Medtech Inventors?
You’re tinkering in garage — or OR — on next big thing. Patent file? Check disclosures twice. Trade secret claim? Ensure zero overlap.
CUTSA’s nationwide-ish via DTSA. Precedent here ripples.
Hype alert: Elist’s PR calls Penuma “revolutionary.” Please. It’s cosmetic dickware. Effective? Jury’s out — pun intended.
Skepticism peak: If secrets were real, why patent relatives? Smells like forum-shopping for max protection.
So.
Watch for ruling. Months away. Till then, inventors: Choose your poison.
🧬 Related Insights
- Read more: EU’s GPAI Code of Practice: Self-Regulation Theater or Actual AI Leash?
- Read more: Inside General Legal: Cracking the Code on $500 AI Contracts
Frequently Asked Questions
What is the Penuma implant and why the lawsuit? Penuma’s an FDA-cleared silicone sleeve for cosmetic penis enhancement. Dr. Elist claims rivals stole four trade secrets; they say patents disclosed everything.
Can you claim trade secrets on patented inventions? Maybe refinements, but Federal Circuit args suggest prior patent pubs likely kill claims under CUTSA.
When will Federal Circuit rule on International Medical Devices v. Cornell? No date set; expect opinion in 3-6 months from March 2026 args.
